Phase II data of brigantinib for relapsed and metastatic NSCLC released
Data from the pivotal Phase 2 ALTA clinical trial evaluating brigatinib in patients with crizotinib-refractory, anaplastic lymphoma…
Browsing: phase 2 trial
Promising results for AGS-003 individualised immunotherapy in kidney cancer
Argos Therapeutics Inc., an immuno-oncology company focused on the development and commercialisation of individualised immunotherapies…